RT Journal Article
T1 Detailed characterization of Act d 12 and Act d 13 from kiwi seeds: implication in IgE  cross-reactivity with peanut and tree nuts
A1 Sirvent, Sofía
A1 Cantó, Belén
A1 Gómez, Francisca
A1 Blanca, Natalia
A1 Cuesta-Herranz, Javier
A1 Canto, Gabriela
A1 Blanca, Miguel
A1 Rodíguez, Rosalía
A1 Villalba, Mayte
A1 Palomares, Oscar
AB Background:Act d 12 (11S globulin) and Act d 13 (2S albumin) are two novel relevant allergens from kiwi seeds that might be useful to improve the diagnostic sensitivity and the management of kiwifruit-allergic patients.Objective:To perform a comprehensive structural and immunological characterization of purified Act d 12 and Act d 13 from kiwi seeds.Methods:Sera from 55 well-defined kiwifruit-allergic patients were used. Act d 12 and Act d 13 were purified by chromatographic procedures. Circular dichroism, mass spectrometry, concanavalin A detection, immunoblotting, enzyme-linked immunosorbent assays, basophil activation tests, and IgE-inhibition experiments were used.Results:Act d 12 and Act d 13 were purified from kiwi seeds to homogeneity by combining size-exclusion, ion-exchange, and RP-HPLC chromatographies. Both purified allergens preserve the structural integrity and display typical features of their homologous counterparts from the 11S globulin and 2S albumin protein families, respectively. These allergens are released from kiwi seeds after oral and gastric digestion of whole kiwifruit, demonstrating their bioavailability after ingestion. The allergens retain the capacity to bind serum IgE from kiwifruit-allergic patients, induce IgE cross-linking in effector-circulating basophils, and display in vitro IgE cross-reactivity with homologous counterparts from peanut and tree nuts.Conclusion:Purified Act d 12 and Act d 13 from kiwi seeds are well-defined molecules involved in in vitro IgE cross-reactivity with peanut and tree nuts. Their inclusion in component-resolved diagnosis of kiwifruit allergy might well contribute to improve the diagnostic sensitivity and the management of kiwifruit-allergic patients.
PB John Wiley & Sons Ltd
SN 1398-9995 (on line), 0105-4538 (print)
YR 2014
FD 2014
LK https://hdl.handle.net/20.500.14352/34912
UL https://hdl.handle.net/20.500.14352/34912
LA eng
NO Spanish Ministerio de Economía y  Competitividad (MINECO)
NO Fondo de Investigación Sanitaria (FIS
DS Docta Complutense
RD 29 abr 2024